

#2  
1631 BP  
5-20-02  
PATENT

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Mark A. Hoffman and  
David P. McCallie, Jr.

) Attorney Docket No. CRNC.83071

) Art Unit:

Serial No. 09/981,248

Filed: October 16, 2001

Title:  
COMPUTER SYSTEM FOR  
PROVIDING INFORMATION  
ABOUT THE RISK OF AN TYPICAL  
CLINICAL EVENT BASED UPON  
GENETIC INFORMATION

RECEIVED

MAY 20 2002

TECH CENTER 1600/2900

CERTIFICATE OF MAILING  
37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the  
U.S. Postal Service, postage prepaid, as First Class Mail in an  
envelope addressed to: Commissioner for Patents, Washington, D.C.  
20231, on:

5/10/02  
Date

J. Dickman  
Signature

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

Enclosed herewith and listed on Form PTO-1449 (also enclosed) are photocopies of  
patents and/or documents which Applicant requests be considered by the Examiner and made of  
record.

U. S. Patent No. 5,833,599, issued November 10, 1998 to Schrier, Robert W. et al.

U. S. Patent No. 6, 081,786, issued June 27, 2000 to Barry, David W., et al.

U. S. Patent No. 6, 067,524, issued May 23, 2000 to Byerly, Baxter H., et al.

U. S. Patent No. 5,758,095, issued May 26, 1998 to Albaum, David, et al.

Lazarou, Jason, et al., "Incidence of Adverse Drug Reactions in Hospital Patients", JAMA, April 15, 1998, Vol. 279, No. 15.

Foubister, Vida, et al., "Expanded Genetic Testing Carries New Legal Risks", American Medical News, October 16, 2000, pp. 13-14.

Evans, William E., et al., "Pharmacogenomics: Translating Functional Genomics into Rational Therapeutics", Science Magazine, Vol. 286, No. 5439, October 15, 1999, pp. 487-491.

Meyer, Urs A., et al., "Molecular Mechanisms of Genetic Polymorphisms of Drug Metabolism", Annu. Rev. Pharmacol, Toxicol. 1997, 37:269-96.

Sundberg, Magnus Ingelman- et al., "Polymorphic Human Cytochrome P450 Enzymes: An Opportunity for Individualized Drug Treatment, 20th Century Advances in Drug Development, J. Clin Pharmacol.2000; 40:930-938.

The Commissioner is hereby authorized to charge any additional fees that are required, or credit any overpayment, to Deposit Account No. 19-2112.

Respectfully submitted,




Jean M. Dickman  
Reg. No. 48,538

JMD:nlh

SHOOK, HARDY & BACON L.L.P.  
One Kansas City Place  
1200 Main Street  
Kansas City, Missouri 64105-2118  
816/474-6550

Attorney Docket No. CRNC.83071  
Serial No. 09/981,248



P-1449 (Modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Attorney Docket No.: CRNC.83071	Serial Number: 09/981,248
	Applicant: Mark A. Hoffman and David P. McCallie, Jr.	
	Filing Date: October 16, 2001	Group:

RECEIVED

MAY 20 2002

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	ISSUE DATE	INVENTOR	CLASS	SUBCLASS	DATE
	5,833,599	11/10/98	Schrier, Robert W., et al.			04/09/96
	6,081,786	06/27/00	Barry, David W., et al.			04/01/99
	6,067,524	05/23/00	Byerly, Baxter H., et al.			01/07/99
	5,758,095	05/26/98	Albaum, David, et al.			02/24/95

## FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

EXAMINER INITIAL	DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

## OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

/	Lazarou, Jason, et al., "Incidence of Adverse Drug Reactions in Hospital Patients," JAMA, April 15, 1998, Vol. 279, No. 15.	
/	Foubister, Vida, et al., "Expanded Genetic Testing Carries New Legal Risks," American Medical News, October 16, 2000, pp. 13-14.	
/	Evans, William E., et al., "Pharmacogenomics: Translating Functional Genomics into Rational Therapeutics," Science Magazine, Vol. 286, No. 5439, October 15, 1999, pp. 487-491.	
/	Meyer, Urs A., et al., "Molecular Mechanisms of Genetic Polymorphisms of Drug Metabolism," Annu. Rev. Pharmacol. Toxicol. 1997, 37:269-96.	
/	Sundberg, Magnus Ingelman- et al., "Polymorphic Human Cytochrome P450 Enzymes: An Opportunity for Individualized Drug Treatment, 20th Century Advances in Drug Development, J. Clin Pharmacol. 2000; 40:930-938.	
EXAMINER		DATE CONSIDERED
EXAMINER: Initial citation if reference was considered. Draw line through citation if not in conformance to MPEP 609 and not considered. Include copy of this form with next communication to applicant.		